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ABSTRACT 
In patients with diabetes, foot ulceration and peripheral artery disease (PAD), it is 
often difficult to determine whether, when and how to revascularise the affected 
lower extremity.  The presence of PAD is a major risk factor for non-healing and 
yet clinical outcomes of revascularisation are not necessarily related to technical 
success.  The International Working Group of the Diabetic Foot updated 
systematic review on the effectiveness of revascularisation of the ulcerated foot in 
patients with diabetes and PAD is comprised of 64 studies describing >13,000 
patients.  Amongst 60 case series and 4 non-randomised controlled studies, we 
summarised clinically relevant outcomes and found them to be broadly similar 
between patients treated with open versus endovascular therapy.  Following 
endovascular revascularisation, the 1 year and 2 year limb salvage rates were 80% 
(IQR 78-82%) and 78% (IQR 75-83%), whereas open therapy was associated with 
rates of 85% (IQR 80-90%) at 1 year and 87% (IQR 85-88%) at 2 years, however 
these results were based on a varying combination of studies and cannot therefore 
be interpreted as cumulative. Overall, wound healing was achieved in a median of 
60% of patients (IQR 50-69%) at 1 year in those treated by endovascular or 
surgical therapy, and the major amputation rate of endovascular versus open 
therapy was 2% vs 5% at 30 days, 10% vs 9% at 1 year and 13% vs 9% at 2 years.  
For both strategies, overall mortality was found to be high, with 2% (1-6%) peri-
operative (or 30 day) mortality, rising sharply to 13% (9-23%) at 1 year, 29% (19-
48%) at 2 years and 47% (39-71%) at 5 years.  Both the angiosome concept 
(revascularisation directly to the area of tissue loss via its main feeding artery) or 
indirect revascularisation through collaterals, appear to be equally effective 
strategies for restoring perfusion. 
Overall, the available data do not allow us to recommend one method of 
revascularisation over the other and more studies are required to determine the 
best revascularisation approach in diabetic foot ulceration. 
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Peripheral artery disease (PAD) affects up to 50% of patients with a diabetic foot 
ulcer (DFU) 1 2 3 and its presence is associated with poor outcomes.  The natural 
history of patients with PAD and DFU is difficult to predict and is affected by more 
than just the severity of arterial disease.  Concurrent infection increases the risk 
of poor outcomes even more, and other factors such as medical co-morbidities, 
microvascular dysfunction, poor glycaemic control and abnormal mechanical load 
may also contribute.  Whilst it is important to recognise and address all of these 
clinical abnormalities, there is evidence that early revascularisation in patients 
with PAD is associated with improved outcomes 4.  However, the decision 
whether, when and how to revascularise is not straightforward. Up to 50% of 
patients for whom revascularisation is not thought technically possible or 
reasonable due to co-morbidities may heal their ulcer within a year without 
revascularisation 5; conversely, amongst those who had a successful and patent 
revascularisation, >20% of patients underwent a major limb amputation within 
12 months in one large series 6. 
 
The anatomical distribution of PAD is more challenging in patients with, as 
opposed to without, diabetes.  There is a predilection for multi-level distal disease 
often involving multiple crural arteries, with long occlusions, poor propensity to 
form collaterals and a high prevalence of medial arterial calcification.  All of these 
factors pose additional technical challenges when attempting revascularisation, 
either by open surgical or endovascular means.  In addition, there are no major 
randomised trials addressing the most appropriate methods of revascularisation 
specifically for patients with DFU and PAD, nor are there informative subgroup 
analyses in general PAD trials.  
 
The International Working Group on the Diabetic Foot (IWGDF) is a multi-
disciplinary group of experts in the management of patients with DFU.  The 
present systematic review of the effectiveness of revascularisation is an updated 
iteration of our previous review, launched in 2015 7, and informs the most recent 
IWGDF guidance addressing the diagnosis, prognosis and management of patients 




We updated our previous systematic review 7, guided by a recent consensus 
document on updating systematic reviews 9.  We searched the MEDLINE and 
EMBASE databases for studies relating to therapies to revascularise the ulcerated 
foot amongst patients with diabetes, updating the previous search and therefore 
capturing any new records published between June 2014 and September 2018.  
The search string is shown in Appendix A.  Two reviewers independently screened 
the abstracts of retrieved articles to determine if they might meet the pre-set 
inclusion criteria, and a third reviewer adjudicated any conflicts.  We accessed full-
text articles of screened articles and assessed them for inclusion; members of the 
IWGDF PAD working group then extracted and verified data. 
 
Inclusion / exclusion criteria 
To be eligible for inclusion, a study was required to meet the following criteria: 1) 
it reported on the outcomes of revascularisation (open or endovascular) for 
patients with DFU and PAD; 2) patients included had objective evidence of PAD 
(such as angiography); 3) >80% of patients included had tissue loss (defined as 
any lesion of the skin breaching the epithelium or ulceration or gangrene); 4) it 
included at least 40 patients with >80% of the population diagnosed with diabetes 
or where the results of at least 30 patients with diabetes were reported 
separately; and 5) it reported on primary outcomes including ulcer healing, limb 
salvage, major amputation or survival.   
Studies reporting only on aorto-iliac disease were excluded, as the treatment of 
supra-inguinal disease is similar in patients with or without diabetes.  Studies 
were excluded if they reported only on medical, pharmacological or topical 
therapies or if they compared different revascularisation technologies.   
We only included studies published in the English language. 
 
Primary outcome measures and definitions 
The primary outcome measures of interest included wound healing, limb salvage, 
major amputation and survival. 
For the purpose of this systematic review, PAD was defined as any flow limiting 
atherosclerotic lesion of the arteries below the inguinal ligament. We accepted the 
diagnosis of diabetes mellitus as it was made according to the individual 
publication.  Tissue loss was defined as any lesions of the skin breaching the 
epithelium, or the presence of ulceration or gangrene.  Early mortality was 
considered within 30 days or within the period of the first hospital admission. A 
major complication was defined as any that resulted in a systemic disturbance of 
the patient or prolonged hospitalisation (or as defined by the individual study). 
 
Data extraction and quality assessment 
This systematic review was performed according to Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidelines 10. Two reviewers 
assessed studies for inclusion based on titles, then a review of the abstract, and 
finally upon review of the full text .  The data for the evidence table were then 
extracted by members of the IWGDF PAD working group, confirmed by other 
members.  Studies were assessed for methodological rigour using the Scottish 
Intercollegiate Guidelines Network (SIGN) guidelines 11. Pooling of data and 
weighting of studies was not possible because of study heterogeneity and the 
generally low quality of evidence.  Data was summarised for individual items as 
interquartile range (IQR) and median (not weighted).  
Patient demographics were summarised, along with specific details of the foot 
lesion where available, and any reported concurrent infection.  Objective 
assessments of perfusion were reported where available.  We made no distinction 
amongst various endovascular techniques (e.g. angioplasty, stenting, subintimal 
angioplasty, atherectomy), which were all referred to as endovascular therapy.  
Neither did we distinguish among methods of open revascularisation (e.g. in situ 





Our updated search included articles published between June 2014 and June 2018 
(Figure 1).  A total of 8759 articles were screened, of which 295 articles were 
assessed for inclusion based on the abstract and 80 assessed for inclusion based 
on the full text.  Ultimately, 7 new studies deemed eligible were identified and, 
when added to those from our previous review 7, a total of 64 studies, comprising 
13,434 patients, are included in this updated systematic review.. There were no 
randomised controlled trials, all included studies were case series (SIGN 3) that 
reported on bypass surgery, endovascular intervention or both techniques used 
in combination.  Few studies provided sufficient detail on severity of PAD or 
baseline foot lesion characteristics, however most studies provided adequate 
information on patient demographics and co-morbidities.  In the event that more 
than one study reported on patients from the same institution, we highlighted this 
in the evidence table, but accepted that it is likely that some patients were 
reported more than once. A complete evidence table with all results from included 
studies can be found in Appendix B. 
 
PICO (patient, intervention, comparison, outcome): What are the aims and 
methods of revascularisation and onward management in a person with diabetes, 
foot ulceration and PAD? 
 
Summary of the literature 
Patient demographics and comorbidities 
Among the 13,434 patients were included, of which 69% (IQRs 68-71%) were 
men, with a median age of 71 (69-72).  As expected, there was a high prevalence 
of cardiovascular comorbidities, including 47% (43-55%) with coronary artery 
disease, 21% (18-23%) with cerebrovascular disease and 21% (20-26%) with 
end-stage renal disease (variably defined). 
 
Clinical outcomes 
It is important to note that the quantitative interpretation of outcomes cannot be 
considered cumulative, as there was a discrepancy of outcome reporting between 
studies and studies had different duration of follow-up.  The results reported for 
each time point are based on a variable number of studies and should not be 
directly compared.   
 
Wound healing 
Only 12 studies reported wound healing as an outcome measure, using variable 
follow-up periods.  Wound healing was achieved in a median of 60% (50-69%) at 
1 year.  Of 3 studies reporting separately on endovascular outcomes, wound 
healing at 1 year was 75% (68-77%), while for two studies reporting on open 
therapy, the median wound healing at 1 year was lower (52%; 46-57%).  
 
Limb salvage and major amputation 
Limb salvage was reported at a predefined time point by 39 studies.  The overall 
limb salvage rates were 82% (IQR 79-89%) at 1 year (based on 28 studies), 86% 
(77-88%) at 2 years (based on 12 studies) and 76% (73-78%) at 5 years (based 
on 14 studies). Following endovascular treatment, 1 and 2 year limb salvages rates 
were 80% (78-82%; based on 9 studies) and 78% (75-83%; based on 5 studies), 
respectively.  In those studies reporting limb salvage following open 
revascularisation (n=25), the rates were: 85% (80-90%) at 1 year (based on 19 
studies) and 87% (86-89%) at 2 years (based on 7 studies). 
 
The definition of major amputation was variable amongst the included studies but, 
where reported with a specified time point, the median rate of major amputations 
within 30 days was 4% (2-5%), which increased at 1 year to 9% (4-12%) and 11% 
(7-18%) at 2 years.   The early (30 day) major amputation rate appeared 
somewhat lower for endovascular therapy when compared to open therapy (2% 
vs 5%) but higher at 1 year (10% vs 9%) and 2 years (13% vs 9%).  However, this 
finding must be interpreted with great caution, due to the heterogeneity of studies 
and patients included and the inconsistency in reporting time points between 
studies. 
 
The rates of minor amputation varied widely, with a median of 38% (IQR 23-
59%).  There were similar rates of minor amputation between patients 
undergoing open (36%, 23-57%) and endovascular (38%, 23-57%) therapies. 
 
 
Mortality and survival 
Peri-operative or 30 day mortality was reported in 30 studies, and was 2% (IQR 
1-5%) overall.  Peri-operative mortality the same following endovascular versus 
open revascularisation (2% vs 2%).  Overall 1 year mortality was 13% (9-23%), 
rising to 29% (19-48%) at 2 years and 47% (39-71%) at 5 years.  At 2 years, the 
highest mortality rates were amongst patients with ESRD (72% in one study 15).  
At 5 years, amongst those in seven studies who underwent open therapy, the 
mortality rate was 43% (39-60%).  In the single study that reported 5 year 
mortality following endovascular therapy it was 74%16, however very small 
numbers remained in follow up at 5 years and the validity of these findings is 
therefore questionable. 
The five studies reporting survival as compared to mortality yielded poorer 
results, with a median survival of 83% (75-87%) at 1 year (four studies) and 39% 
(26-46%) at 5 years (four studies), which translates into mortalities of 17% and 
62% at 1 and 5 years, respectively. 
 
Specific revascularisation strategies 
Pedal bypass 
Among the twelve studies that reported on pedal bypass surgery, the median 1, 2 
and 5 year limb salvage rates were 86% (80-92%), 85% (68-86) and 87% (78-
95%). Peri-operative mortality was similar to that in the overall population at 2% 
(1-4%), with 1 year, 2 year and 5 year mortality rates of 14% (11-32%), 48% (32-
60%) and 42% (39-45%), respectively.  These outcomes are again based on a 
variable number of studies, with different duration of follow-up, reporting at each 
time point.   
 
Infra-popliteal angioplasty 
Eight studies reported exclusively on infra-popliteal angioplasty; at one year the 
median rate of wound healing was 71% (65-75%) and limb salvage was 77% (71-
85%).  
In a review of 448 patients (83% with diabetes) who underwent infrapopliteal 
angioplasty for tissue loss (86%) or rest pain (14%), there was no significant 
difference in major amputation rates at one year between single-vessel 
angioplasty and multiple-vessel intervention (16% vs 10%, p=0.24)17. Another 
smaller study (n=92) 18, also comparing single versus multiple endovascular 
revascularisation attempts, found no difference in outcomes between the two 
groups.  In a third study of 92 patients undergoing endovascular therapy, the 
presence of a complete pedal arch following the intervention was associated with 
increased rates of wound healing, limb salvage and survival at 1 year compared to 
absence of a complete pedal arch 19. 
 
Angiosome-directed revascularisation 
Angiosome-directed revascularisation is a method of improving perfusion of an 
area of tissue loss directly, via its feeding artery (also called direct 
revascularisation, DR).  This is based on the theory that the foot can be divided 
into 3 dimensional units of tissue (angiosomes), each of which is supplied by a 
specific feeding artery.  By targeting a feeding artery that directly supplies an area 
of tissue loss, the concept is that this is the best way to improve perfusion to that 
specific area.  The more traditional ‘best vessel approach’ can be considered non-
angiosome directed or indirect revascularisation (IR), whereby the most suitable 
target vessel is chosen for revascularisation, regardless of its anatomical location.   
The majority of literature relating to outcomes based on the angiosome concept 
in patients with diabetes and foot ulcers is retrospective. We identified eight such 
studies, all of which were retrospective case series or cohort studies and had a 
high risk of bias.  Six studies concluded that direct revascularisation according to 
the angiosome concept was associated with higher rates of wound healing when 
compared with indirect revascularisation 20 18 21 22 23 24, however only four of these 
studies reported higher rates of limb salvage.   
In one study 18, patients who underwent indirect revascularisation (ie non-
angiosome directed) were stratified further by the role of collaterals – those in 
whom pulsatile flow was restored to the affected area indirectly (ie not targeted 
to the feeding artery) but by collaterals (indirect revascularisation, via collaterals; 
IRc) and those in whom there were no collaterals between the target artery and 
the affected angiosome (indirect revascularisation, no collaterals).  In this series, 
92 patients underwent endovascular infra-popliteal intervention (including those 
with concurrent supra-popliteal angioplasty), and the outcomes were similar for 
DR and IRc – limb salvage rates were 89% and 85% at 2 years and wound healing 
was 66% and 68% at 12 months.  However, in those patients who underwent 
indirect revascularisation with no collaterals, limb salvage and wound healing 
rates were poor (59% and 7%, respectively). 
A more recent study compared angiosome-based intervention during 
endovascular and open techniques in a series of 545 patients with diabetes and 
foot ulceration undergoing a first-time infra-popliteal revascularisation 23.  The 
highest rates of wound healing were in patients who underwent open 
revascularisation classified as DR (77% healing at 1 year) and the worst rates 
were in those who underwent endovascular treatment classified as IR (52% 
healing at 1 year).  Amputation rates were also highest in the IR endovascular 
group, but if IR was achieved via collaterals then this improved limb salvage. 
 
Significant clinical comorbidities 
End-stage renal disease 
In the nine studies that analysed patients with end-stage renal disease (ESRD, 
defined variably) separately, its presence increased peri-operative mortality 
(4.6%, 2.6-8.8%) and high mortality over 5 years (48% and 72% at 2 years 25 26, 
56% at 3 years 27 and 91% at 5 years 12), albeit based on small study numbers.  For 
those who did survive to 1 year, salvage rates were 70% (65-70%). 
 
Infection 
Whilst it is a well recognised risk factor for poor outcomes in patients with 
diabetes and foot ulceration, only two studies specifically reported on outcomes 
in patients with diabetes, PAD and foot infection 28 29. Both studies were 
retrospective case series of patients with an acutely infected ulcer.  In a study of 
53 patients who underwent pedal bypass 28, 20% required minor amputation 
prior to bypass; however, the resulting limb salvage was excellent, at 98% at 1 
year, 98% at 2 years and 95% at 3 years.  In a study of 114 patients with foot 
infection, 38% underwent open revascularisation and the overall limb salvage for 
the case series was 87% at 2 years and 73% at 4 years 29  
 
 
Evidence statement: Evidence is inadequate to establish whether an 
endovascular, open or hybrid revascularisation technique is superior in restoring 
blood flow and improving prognosis in patients with diabetic foot ulceration and 
PAD 
 
Quality of the evidence: Low, based on cohort studies and case series 
 
Evidence statement: Restoration of direct blood flow to at least one of the foot 
arteries, preferably the artery that supplies the anatomical region of the ulcer is 
associated with the best outcome. Both revascularisation directly to the area of 
tissue loss via its main feeding artery or indirect revascularisation through 
collaterals, appear to be equally effective strategies for restoring perfusion 
 




 This systematic review is an update of the version launched in 2015 30 and, in 
addition to the 56 studies included previously, includes a further seven studies 
describing outcomes of revascularisation in patients with diabetes, PAD and foot 
ulceration.  All of the new studies were retrospective reviews of medical care 
encounter databases in either single or multiple institutions across the world and 
had a high risk of bias, as well as significant heterogeneity in included participants 
as well as outcome reporting.   Of particular note, none of these new studies 
included a control group.  There was also inconsistency in reporting of some key 
variables such as the severity of arterial perfusion deficit, indication for 
revascularisation and ulcer characteristics.  For these reasons, it was not possible 
to pool the data or conduct a meta-analysis. 
 
One of the main obstacles in revascularisation of patients with diabetes is the often 
complex, distal pattern of disease, which poses a challenge for performing both 
endovascular and open therapy. Crural vessel angioplasty and distal bypasses are 
often more time-consuming and technically demanding than revascularisation 
with a more proximal outflow target vessel, and thus require additional expertise.  
The presence of multi-level disease, highly calcified lesions and paucity of 
collaterals each further contributes to this challenge. Overall, however, the 
current rates of reported limb salvage presented here (82% at 1 year and up to 
78% at 5 years) are greatly improved on those reported by two studies 
documenting the natural history of patients with diabetes and foot ulcers for 
whom revascularisation was deemed unsuitable (50-54% at 1 year)  31 5. Even 
amongst patients included in this review who underwent pedal bypass or crural 
angioplasty, limb salvage rates were reported as 86% and 77%  at 1 year. 
 
Because there are no randomised trials comparing methods of revascularisation 
specific to patients with diabetic foot disease, it is not possible to determine which 
method of revascularisation is more effective.   Results from the Bypass versus 
Angioplasty in Severe Ischaemia of the Leg (BASIL) trial, the only completed RCT 
comparing open or endovascular treatment of severe limb ischaemia, published 
in 2005 32, cannot be directly extrapolated to patients with diabetes and foot 
ulceration, as only around 40% of the patients in BASIL had diabetes and the main 
pattern of disease was femoropopliteal.  Moreover, there has been substantial 
advancement of endovascular technologies that were not captured by the BASIL 
trial.  A more recent sub-group analysis of the BASIL trial that included only those 
enrolled patients with infra-popliteal disease demonstrated no difference in 
outcomes in open versus endovascular intervention 33; however since <50% of 
these patients had diabetes, this information is again not directly transferable to 
the problem of the best revascularisation method for the diabetic foot.  At the time 
of writing, BASIL-2 is recruiting patients with severe limb ischaemia due to infra-
popliteal disease (with or without the presence of femoropopliteal disease) and 
will compare vein bypass-first versus best endovascular-first revascularisation.  
Given that a higher proportion of patients in BASIL-2 are likely to have diabetes, 
this study may facilitate further sub-group analyses that may be more informative 
for patients with diabetic foot ulcers and PAD. 
 
Nevertheless, the outcomes presented in this review are broadly similar for open 
and endovascular therapy, albeit in very heterogeneous populations.  Wound 
healing was infrequently reported as an outcome (and variably defined) and 
whilst it appeared that endovascular compared to open revascularisation was 
associated with improved ulcer healing at 1 year (75% vs 52%), one of the two 
studies reporting open therapy included patients in whom almost 75% had ultra 
distal bypass, which may skew the overall outcomes due to its technical 
complexity. Otherwise, the rates of limb salvage and major amputation were 
broadly similar between patients undergoing open versus endovascular 
treatment. The results of both of these methods, however, will of course depend 
on the expertise and resources at a given institution.   Our review does not 
summarise the data pertaining to technical success or feasibility of 
revascularisation in patients with diabetes, the most important outcomes to 
report are in our opinion clinical.  Whilst the aim should be to use a durable 
revascularisation approach, the overall goal of healing the foot may be met even if 
a revascularisation site does not remain patent in the long term.   
 
The angiosome concept is an area of much debate.  Traditionally, the best vessel 
is chosen as the target for revascularisation, with a goal of restoring inline 
pulsatile blood flow to the foot through any means.  More recently described, 
angiosome-directed revascularisation is based on the principle that the foot can 
be divided into six 3-dimensional blocks of tissue, each supplied by a feeding 
artery.  The theory is that by identifying the specific feeding artery to an area of 
tissue loss and targeting that artery for revascularisation (ie direct 
revascularisation; DR), restoration of pulsatile blood flow directly to an area of 
tissue ischaemia renders it more likely to heal.  Alternatively, non-angiosome 
directed therapy (indirect revascularisation; IR) adopts the ‘best vessel’ approach, 
whereby the most suitable target artery is chosen, regardless of whether it relates 
to the area of tissue loss and blood flow is therefore restored to the area by 
collaterals.  Given that patients with diabetes typically have poor collaterals, it 
seems intuitively that angiosome-directed revascularisation might be more 
effective.   
The results of six out of eight retrospective studies in this review suggest that 
direct revascularisation (ie angiosome-based therapy) is associated with 
improved wound healing and in four studies, this translated to improved limb 
salvage.  Those of one study 18 suggest that indirect endovascular 
revascularisation through collaterals has similar outcomes to direct 
revascularisation and that both offer significantly improved rates of limb salvage 
and wound healing when compared to indirect revascularisation without 
collaterals. These findings are reflected in two recent meta-analyses that 
combined include >4000 limbs with foot ulcers (>80% of which had diabetes), 
which both concluded that endovascular IR significantly improves wound healing 
and major amputation rates, but that, in the presence of collaterals, IR and DR have 
similar outcomes 34 35.  However, the populations included were highly variable, 
the definitions poorly defined and it is not possible to draw any firm conclusions 
from these data.  Despite this, we think it would be sensible to pursue an 
angiosome-based revascularisation strategy if possible, particularly in patients 
with diabetes who have poor collaterals and may therefore benefit from the 
restoration of blood flow directly to the area of tissue loss.   
 
That said, since several patients, >20% of patients in one study, who undergo a 
successful revascularisation procedure will still require a major amputation 
within 12 months 6, there is clearly more to the story than optimising perfusion.  
While other clinical variables that affect outcomes (such as infection, wound 
characteristics, neuropathy, and comorbidities), it is difficult to know what 
proportion each of these factors contributes to an individual patient’s chance of 
clinical success.  The evidence indicates that patients with diabetes, ulceration and 
severe perfusion deficit should be considered for early revascularisation, however 
the role for intervention in those with mild to moderate ischaemia is less well 
defined.  The studies included in our review provided few data about the perfusion 
deficit, the duration of attempted conservative management or the indication for 
vascular investigation and treatment.  In addition, there is no known threshold 
value of perfusion towards which we should aim when attempting 
revascularisation.  So as part of a goal to optimise all approaches to heal a diabetic 
foot ulcer, these patients mild to moderate ischaemia should be investigated 
further for the presence of a perfusion defect amenable to revascularisation if 
there is no significant improvement in healing within 4-6 weeks of optimal care.   
 
Unfortunately, there are some clinical characteristics that contribute significantly 
to poor outcomes but cannot be optimised.  ESRD is a known risk factor for foot 
ulceration and major amputation in patients with diabetes 36 and outcomes of 
revascularisation in this group are typically poor.  Our review found that patients 
with ESRD undergoing revascularisation had lower 1 year limb salvage rates (70% 
vs 82%).  Moreover, there was increased peri-operative mortality, and  >50% of 
patients were dead at 3 years and up to 90% at 5 years.  This appears much higher 
than the overall median mortality rates of almost 30% at 2 years and 46% at 5 
years. 
 
The poor survival rates in patients with diabetes, PAD and foot ulceration is in a 
large part attributable to the systemic nature of arterial disease.  Many patients 
with PAD will also have ischaemic heart disease and cerebrovascular disease on 
presentation.  It is imperative, therefore, to ensure that all patients with PAD 
receive comprehensive medical management of concomitant cardiovascular 
disease and control of cardiovascular risk factors, including at a minimum, 
smoking cessation, anti-platelet and statin therapy. 
 
This systematic review once again highlights the paucity of robust evidence to 
guide the treatment of patients with diabetes, PAD and foot ulcers.  To date, there 
are no randomised trials of endovascular versus open revascularisation in these 
patients and the vast heterogeneity of the available data precludes meaningful 
data pooling or meta-analysis.  There remains an urgent need for improved 
research in this field.  Better study design, use of pre-defined and standardised 
outcomes reporting, including wound healing, will go some way towards 
producing better quality evidence.  However, the fate of a patient with diabetes, 
foot ulceration and PAD remains difficult to predict, and is affected by a multitude 
of clinical characteristics that cannot always be identified and ameliorated.  The 
high mortality rates observed amongst these patients should alert the clinician to 
the significant contribution of concomitant cardiovascular diseases to outcomes, 
and the overall frailty of the patient cohort.  The goals of revascularisation should 
be reflected in the decision-making process between both the patient and the 




This updated systematic review of studies including more than 13,000 patients 
with diabetes and PAD demonstrates adverse high event rates even when 
revascularisation is undertaken.  This highlights the importance of optimising care 
of concomitant cardiovascular disease, including medical management and 
lifestyle modification, particularly in light of the mortality rates of almost 50% at 
5 years, worse than many common cancers. There is no appreciable difference in 
clinical outcomes when comparing endovascular and open therapy and both 
remain reasonable strategies, depending on the local expertise.  Planning a 
revascularisation approach based on the angiosome concept appears to be a 
sensible approach in patients with diabetes (especially in those undergoing 
angioplasty), who typically have poor collateralisation and would likely benefit 
from revascularisation directly to the feeding artery at the area of tissue loss.  
However, the data to support this concept are almost entirely retrospective, 
lacking in standardisation of techniques, definitions and outcome measures.  More 
robust evidence is therefore required in order to understand the best strategy for 
revascularisation in patients with diabetes, foot ulceration and PAD. 
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